Summary
Regulatory B (B reg ) cells are characterized by various membrane markers and the secretion of different inhibitory cytokines. A new subset of B reg cells was identified as CD5
hi Fas-ligand (FasL) hi . Their main reported role is to suppress anti-viral and anti-tumour immune responses, and, hence they have been dubbed 'killer' B cells. In this study, we aim to assess the role of these cells in chronic hepatitis C virus (HCV) infection, and determine if they contribute to the increased viral load and persistence of HCV and its related autoimmunity. (i) FasL expression on CD5 hi B cells is increased significantly in HCV-infected patients compared to healthy individuals [28Á06 6 6Á71 mean fluorescence intensity (MFI) 6 standard error of the mean (s.e.m.), median 5 27Á9 versus 10Á87 6 3Á97 MFI 6 s.e.m., median 5 10Á3, respectively, P < 0Á0001].
(ii) Killer B cells from HCV patients increased autologous CD4 1 T cell apoptosis compared to the apoptosis in healthy individuals [39Á17% 6 7Á18% mean 6 standard deviation (s.d.), median 5 39Á6 versus 25Á92 6 8Á65%, mean 6 s.d., median 5 24Á1%, P < 0Á0001, respectively]. A similar increase was observed in CD8 1 T cell apoptosis (54Á67 6 15Á49% mean 6 s.d., median 5 57Á3
Introduction
Hepatitis C (HC) is the second most common infectious disease worldwide, with 130-150 million cases, and 500 000 deaths annually due to cirrhosis or liver cancer. The efficient host immune reaction against the various hepatitis C virus viral proteins determines viral persistence, the extent of infected hepatocytes and the severity of liver inflammation. It has been shown that the persistence of the hepatitis C virus (HCV) is associated with the increased presence of autoantibodies. Anti-nuclear antibodies (ANA), rheumatoid factor (RF) and anti-cardiolipin antibodies (aCL) are the most reported autoantibodies in HC patients with a prevalence of positivity in more than 20% among them [1] . Once primary immunization has occurred, the repeated generation of apoptotic material (during persistent viral infection) might efficiently rechallenge the primed immune system. This capacity for immune-derived autoamplification is possibly a critical principle underlying systemic autoimmune disorder [2] . The first line of defence is always the efficient peripheral immune responses against HCV antigens, mainly cytotoxic T cell response and natural killer (NK) cell activity. Both T and NK cells were shown to eliminate HCV-infected cells by over-expressing Fas ligand (FasL) and/or producing granzyme B (GranB). In the early phase of infection, B cells produce neutralizing antibodies against different virus epitopes, mainly against envelope glycoproteins E1 and E2 [3] . Most of these antibodies fail to block the entry of the virus into host cells, and therefore the role of humoral anti-viral responses remains limited. Chronic HCV infection and its persistence were reported to be the result of impaired NK cell function and insufficient interferon (IFN)-g production, in addition to increased secretion of interleukin (IL)-10, leading to the failure of HCV cleaning. We reported previously that enhanced peripheral T cell apoptosis in chronic HCV infection was associated with an increased viral load, autoimmunity and liver disease severity [4, 5] .
Of the many possible mechanisms by which HCV infection increases the tendency of T cells to undergo apoptosis, worth mentioning are: (1) down-regulation of major histocompatibility complex (MHC) class II and B7 molecules on HCV-infected dendritic cells, which attenuates the delivery of co-stimulation; (2) inhibition of the production of IFN-g and IL-12, leading to an enhanced responsiveness to IL-10 modulating effects and down-regulation of T helper type 1 (Th1) responses; (3) induction of autoimmune responses due to cross-reactions between HCV core proteins and cryptic epitopes on activated T cells; and (4) enhancement of T cell apoptosis by causing G1/S arrest and c-myc up-regulation [5] . In order to facilitate an efficient process of anti-viral cytotoxicity, a balance between regulatory T cell (T reg ) function and efficient effector T cell function is required. In this respect, T reg expansion and their increased suppressive function (induced by HCV signalling) was found to be correlated with altered abilities of effector T cell responses and the persistence of HCV infection followed by its escape to the liver [6] . In this regard, CD4 hi CD1d hi , IL-10 and transforming growth factor (TGF)-b-producing and showed an increase in T reg function through a cell-to-cell mechanism [10] . In recent years, many studies have reported that CD5 hi B cells are a main source of IL-10 production, resulting in them being considered to be another member of the B reg cell family [11, 12] . CD5
hi B reg cells were also presented as expressing FasL, thereby showing that they play a role in regulating different immune responses by inducing effector T cell apoptosis [13] . In one study, FasL expressing B lymphocytes were purified from the spleen of MRL/lpr mice, and were shown to be potent cytotoxic effectors against Faspositive targets. The level of FasL expression increased with the extent of the cell-surface activation marker CD69, indicating that expression of FasL is up-regulated in parallel with the activation state of B cells [14] . Later, in a T cellreceptor transgenic mouse model of collagen-induced arthritis, altered T cell death and enhanced severity of arthritis correlated with reduced splenic CD5 1 FasL 1 B cells. Appropriately dubbed 'killer B' cells, it was suggested that this subset of B regs may provide a novel mechanism for inducing T cell death as a treatment for arthritis [15] . With this in mind, CD5
hi FasL hi B cells were reported to play a crucial role in the persistence of some pathogens and in their escape from efficient T cell immune responses. In a very early study, in a murine model of Schistosoma mansoni infection, a subset of splenic CD19
1 B cells were shown to be FasL-expressing and mediators of CD4
1 T cell apoptosis, thus inhibiting anti-pathogen immune responses [16] . Several viral infections, including the human immunodeficiency virus and Epstein-Barr virus (EBV), have been reported to increase Fas (CD95) on effector CD4
1 T cells and FasL expression on B cells, leading to increased T cell apoptosis and the evasion of viruses from cellular cytotoxic immune responses. The mechanisms by which viruses and parasites induce FasL expression are still not clear enough [17] . Although it has been mentioned in the literature throughout the last decade, the issue of killer B cells and their contribution to viral persistence remains enigmatic [18] . In this study we aim to analyse, for the first time, the status of this unique subset of B regs in patients suffering from chronic HCV infection. We assume that increased numbers and expression of FasL on CD5 hi B cells is followed by these cells' increased killing function, and are thus possibly associated with HCV persistence, increased viral load and disease severity.
Patients and methods

Patients
Our study included 41 patients (15 females and 26 males, mean age 5 53Á4 years, range 5 34-66 years) in whom chronic HCV infection was established by their having increased liver enzymes, positive serum anti-HCV antibodies [assessed by enzyme-linked immunosorbent assay (ELISA) II; Abbot Laboratories, North Chicago, IL, USA] and detectable HCV RNA (polymerase chain reaction). All patients were studied before any specific anti-viral therapy was given. We excluded HCV patients in whom other immune-mediated diseases were diagnosed and to whom any immune-modulated treatments were given. HCVinfected patients are followed at the Liver Disease Clinic, Bnai-Zion Medical Center and at the Liver Disease Center of Carmel Medical Center, Haifa, Israel. All patients were assessed for the presence of liver enzymes, serum HCV antibodies, a panel of autoantibodies including ANA, antismooth muscle antibodies (anti-sm), RF and aCL. A viral load assessment was performed on all patients and was tracked periodically as part of the follow-up. Forty-five healthy age-and sex-matched individuals served as a control group. Informed consent was obtained from all the participating individuals and the study was approved by the local ethics committee for clinical studies.
Methods
HCV quantification. HCV RNA concentration in serum was measured using an Amplicor Monitor Test Kit (Roche Diagnostic Systems, Basel, Switzerland). This test includes an RNA quantification standard of a known copy number that is co-amplified with a target and is used to calculate the copy level of the sample by colorimetric assay following hybridization to a specific probe. All antibodies were detected using commercial ELISA kits as part of our routine evaluation of all HCV patients.
T and B cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll Paque density gradient. The CD4
1 T cells or CD8 1 T cells were positively isolated from PBMCs using anti-human CD4 or CD8 microbeads, respectively [magnetic-activated cell sorting (MACS) technology; Milteyni Biotec, Bergisch Gladbach, Germany], according to the manufacturer's instructions. Achieved purity was assessed by fluorescence activated cell sorter (FACS) analysis and was always found to be > 96%. The CD19 1 B cells were positively isolated in order to characterize CD5 low versus CD5 hi B cells. However, B cells were also negatively isolated from PBMCs (to be used later for B cell sorting) using the EasySep TM human B cell enrichment kit (StemCell Technologies Inc., Vancouver, BC, Canada), according to the manufacturer's instructions. The desired unlabelled fraction was poured off into a final collection tube, thereby achieving a purity of > 96%.
Assessment of CD5
hi FasL hi B cells by flow cytometry Isolated CD19 1 B cells (both naive and activated) were divided into three tubes, and stained as follows: (1) 
Statistical analysis
The assessment of data normality was performed using the D'Agostino-Pearson test, and a comparison of the differences between two groups and assessment of the median values was performed using the Mann-Whitney nonparametric test. A comparison among three groups was performed using Kruskal-Wallis one-way analysis of variance (ANOVA), followed by Dunn's post-hoc test. In order to determine the difference between the different autoantibody levels (negative low high), ANOVA and post-hoc tests using Tukey's procedure were performed. A two-tailed P-value of 0Á05 or less was considered to be statistically significant.
The correlation coefficient (r s ) of the correlation between the percentage of killer B cells and viral load was determined using Spearman's correlation test. In order to determine the difference between the different autoantibody levels (negative low high), ANOVA and post-hoc tests using Tukey's procedure were performed. A two-tailed P-value of 0Á05 or less was considered to be statistically significant.
Results
Hepatitis C patients
All patients were studied after HCV infection was confirmed by detecting HCV RNA genomes, and by recording increased levels of antibodies to the hepatitis C virus (anti-HCV). All patients had elevated liver enzymes to at least one of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyltransferase (GGT). In all patients, serology was performed for the detection of HCV-related autoantibodies. Positive RF was found in 16 of 41 patients (39%), but only in three of 45 healthy controls (7%). ANA positivity was found in 17 of 41 patients (41%), but only in four of 45 healthy controls (9%). For detailed results, see Table 1 .
Characterization of killer B cells
In order to define the phenotypical markers of killer B cells, purified B cells from 12 healthy controls were positively selected from PBMCs using CD22 microbeads (purity > 98%) and assessed for 48 h as either nonstimulated or stimulated cells, as described above. In normal controls, the amount of CD19 (Fig. 1) . The expression of IL-10 and the death molecules GranB and perforin by CD5 low and CD5 hi B cells were also significantly higher on CD5 hi B cells (2Á37 6 1Á04 MFI 6 s.e.m., median 5 2, versus 5Á41 6 1Á82 MFI 6 s.e.m., median 5 5Á9, P 5 0Á0003; 2Á07 6 0Á80 MFI 6 s.e.m., median 5 1Á9 versus 11Á59 6 8Á94 MFI 6 s.e.m., median 5 8Á6, P < 0Á0001; 1Á82 6 1Á02 MFI 6 s.e.m., median 5 1Á8 versus 4Á15 6 2Á25 MFI 6 s.e.m., median 5 3Á8, P 5 0Á0069, respectively). This expression was increased significantly when B cells were stimulated. Again, the abovementioned markers, namely FasL, IL-10, GranB and perforin, were increased further on both stimulated CD5 low and CD5
hi when compared to that on naive B cells. This expression was significantly higher on CD5 hi compared to CD5 low B cells; see detailed data in Table 2 .
Killer B cells in healthy controls versus HCV patients
Aiming to establish the difference in the amount and level of Fas-ligand expression of killer B cells in HCV patients compared to healthy controls, B cells were isolated from the peripheral blood of 41 patients suffering from chronic HCV infection and from 45 healthy controls and then sorted to CD5 high /CD5 low B cells (see Methods section). Using flow cytometry analysis, we could not detect any difference in FasL expression on the surface of CD19 1 CD5 low B cells in HCV patients compared to healthy controls (6Á91 6 1Á33 MFI 6 s.e.m., median 5 6Á3 versus 4Á62 6 1Á98 MFI 6 s.e.m., median 5 4Á5 respectively, P 5 0Á053; data not shown). The expression of FasL on the surface of sorted CD19
1 CD5 hi cells, however, was found to be significantly higher in HCV patients when compared to the healthy controls (28Á06 6 6Á71 MFI 6 s.e.m., median 5 27Á9 versus 10Á87 6 3Á97 MFI 6 s.e.m., median 5 10Á3, respectively, P < 0Á0001); see Fig. 2a . Furthermore, killer B cells (CD19
1
CD5
hi FasL hi ), were found to be increased significantly in HCV patients when compared to the amount T cell apoptosis in HCV patients compared to healthy controls (54Á67 6 15Á49%, mean 6 s.d., median 5 57Á3 versus 21Á07 6 7Á4%, mean 6 s.d., median 5 20%, P 5 0Á0006, respectively).
The induction of T cell apoptosis by killer B cells is prevented by the anti-FasL neutralizing antibody
Aiming to prove the concept of apoptosis being dependent upon FasL expression on killer B cells, we used anti-FasL neutralizing monoclonal antibody to block biological activity of FasL. to 33Á7 6 9Á76%, mean 6 s.d., median 5 32Á9% in the presence of the isotype control, and decreased significantly to 21Á17 6 5Á72%, mean 6 s.d., median 5 21Á25% in the presence of anti-FasL neutralizing antibody; P 5 0Á0039; see Fig.  5a . In HCV patients, the analysis of results obtained from seven experiments demonstrated that the same situation as was found when CD4 1 T cells were cultured with the isotype control or with neutralizing monoclonal antibody in healthy controls. When CD4 1 T cells were co-cultured with
, however, the apoptosis rate rose to 44Á63 6 10Á13%, mean 6 s.d., median 5 45Á9% in the presence of the isotype control, and decreased significantly to 22Á33 6 11Á83%, mean 6 s.d., median 5 20Á05% in the presence of the anti-FasL neutralizing antibody; P 5 0Á0041; see Fig. 5b .
An increase in the number of killer B cells is associated with an increased viral load and autoimmunity
Aiming to prove the concept that an increased viral load and the presence of autoimmunity in HCV patients are 
CD5
hi FasL hi , the rate of apoptosis rose to 39Á17 6 7Á18% mean 6 s.d., median 5 39Á6, P < 0Á0001. associated strongly with increased killer B cells, the percentage of CD19 1 CD5 hi FasL hi B cells was assessed in correlation with the viral load and with different autoantibodies in HCV patients. We were able to demonstrate that the viral load in HCV patients is correlated strongly and positively with the increase of killer B cells, r s 5 0Á55, P < 0Á01; see Fig. 6a . One-way ANOVA was used to show how the presence of RF and ANA effects the percentage of killer B cells (overall ANOVA significance: P 5 0.0264 and P 5 0Á0424, respectively). Post-hoc tests using Tukey's procedure show that the order of the levels are negative low high and that the difference between high and negative is significant (P 5 0Á0198, P 5 0Á0357, respectively). See Fig. 6b,c. 
Killer B cells in chronic HCV infection
Discussion
Historically, most studies have focused upon understanding how HCV infection is cleared by efficient immune responses; namely, natural killer cells and cytotoxic T cells. These responses, however, sometimes fail, and when they do HCV infection becomes chronic, thereby damaging the liver by inducing hepatocyte apoptosis. Seeking to understand that HCV chronicity and its escape from efficient immune responses is frequent, researchers have looked for the mechanisms by which this evasion occurs. The exhaustion of HCV-specific T cells and NK cells is usually balanced by an increase in immune regulatory function; namely, an increased level of anti-inflammatory T regs . Many researchers have linked the failure of HCV clearance and progression to chronic infection with significantly higher IL-10 production and a relative absence of IFN-g and IL-2 production. In contrast, deficient CD4 1 T cell responses dominated by IFN-g-producing cells and down-regulation of IL-10-producing cells [20] . In chronic HCV infection, IFN-abased therapy gradually enhances CD4 1 T cell responses, whereas IL-10 and TGF-b serum levels are decreased [21] . In one of our early studies, we demonstrated that increased spontaneous CD4 1 T cell apoptosis in peripheral blood may be an important mechanism by which HCV escapes efficient immune responses. In the last few years, the role of B cells in fighting HCV infection has been gaining more attention. Being the source of neutralizing anti-HCV antibodies, they are believed to prevent envelope glycoproteins E1 and E2 from entering host cells and modifying the course of acute HCV infection. Chronic HCV infection, by itself, is not sufficient to activate mature memory B cells. The presence of RF in the serum of these patients with chronic HCV infection, however, was found to be associated with a more pronounced state of over-representation of these memory B cells, and that by persisting in the blood, the latter probably play a role in the attempt to clean HCV from the host [22] . So far, little is known about the role of B reg cells in the persistence of HCV. However, in chronic HBV, CD19 1 CD24 hi CD38 hi -producing IL-10 B reg cells were reported to increase when compared to healthy controls and were able to suppress the response of HBVspecific CD8 1 T cells [23] . Another subset of B reg cells,
hi , was also found to be increased in both HCV and HBV patients, and to be correlated with HCV RNA in monocytes of patients' sera, as well as with poor virus elimination [24] . Recently, studies have found that CD5 hi B reg cells are important in producing IL-10 when specifically activated [25] . Similar to the abovementioned subsets of B reg cells, these were also reported to play a role in immune-mediated disorders. Of great interest are CD5 hi B cells highly expressing FasL, and are therefore called killer B cells. Their role in the spread of malignancy and the persistence of viral infections such as EBV and HIV has been emphasized in the literature [17, 26] . Many studies have discussed the issue of HCV entry into immune cells, alluding to its importance for its spread and maintenance of infection. CD81, CLDN1 and other receptors were assessed for their ability to attach HCV. Their overexpression on NK or T cells (although not fully proved) were suggested to be entry receptors for HCV. All this may explain why both FasR and FasL are over-expressed on the T cells of chronic HCV patients, leading to their increased apoptosis and the escape of HCV from clearance. It is important to mention that increased T cell apoptosis is a result of antigen-specific mediated killing, and therefore is not associated with any global T cell immune suppression. Our main aim in this study was to demonstrate the expansion of killer B cells in HCV-infected patients and how they induce effector T cell apoptosis in a FasL-dependent mechanism. It should be mentioned, however, that the wellreported increase of FasR expression in virally infected T cells is an independent factor contributing to the increased effector T cell apoptosis. In addition, we demonstrate the important fact that increased FasL expression on CD5 hi B cells and the expansion of this subpopulation of B cells in HCV patients is correlated positively with an increased viral load and with related HCV autoimmunity. Unfortunately, we were unable to show that this increase is correlated positively with HCV disease severity. This limitation in our study was due to the fact that the severity of HCV was evaluated using different assays in the two centres where HCV patients are followed. Future studies should evaluate this issue. In this respect, it is of importance to assess the level of killer B cell expansion vis-a-vis HCV severity and its possible down-regulation following successful treatments and HCV elimination. The over-expression of death molecules such as programmed cell death 1 (PD-1), perforin, GranB and FasL on immune cells, mainly those infected with HCV, suggests that targeting them may become a successful therapeutic strategy in the battle against HCV. In this regard, HCV-specific T cell function was assessed. Anti-viral T cell responses were restored following their incubation with anti-PD-1 antibody. This suggests that PD-1/programmed cell death ligand 1 (PD-L1) blockade should be considered a beneficial therapeutic option in long-lasting chronic HCV infection [27] . Anti-PD-1 antibody was also given to chimpanzees with persistent HCV infection. Here, the control of HCV replication was associated with restoration of intra-hepatic CD4 1 and CD8 1 T cell immunity against multiple HCV proteins [28] . The beneficial effect of anti-Fas ligand in animal models of chronic hepatitis was reported more than a decade ago. In an animal model of chronic hepatitis, the development of hepatocellular carcinogenesis, hepatocyte apoptosis, proliferation and liver inflammation were all prevented by the neutralization of FasL [29] . Anti-perforin neutralizing antibody was assessed for its ability in reducing myocardial damage in BALB/c mice (used as a model for viral myocarditis). The injection of anti-perforin antibody into these mice reduced myocardial viral titres, the extent of cardiomyocyte apoptosis and down-regulation of messenger ribonucleic acid and caspase-3 expression [30] . Our finding of FasL being over-expressed on killer B cells strengthens the theory regarding their important role in the persistence of HCV and, hence, the therapeutic direction of combining anti-FasL antibodies in the arsenal of anti-viral therapy. Future studies should focus upon evaluating killer B cells following anti-viral therapy and to determine whether this could restore the over-activity of this B cell subset. It is possible that by adding anti-FasL and anti-PD-1 antibodies to other anti-viral therapies we could achieve better and, perhaps, longer-lasting clearance of HCV. In conclusion, killer B cells should be taken into consideration when HCV persistence is studied, and their role in HCV chronicity and disease severity should be defined more clearly.
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